Transition falls on ELND005 safety analysis

Shares of Transition Therapeutics Inc. (TSX:TTH; NASDAQ:TTHI) fell on Tuesday after an analysis of the Phase II AD201 trial for Alzheimer's disease by an independent safety monitoring committee showed a greater rate of serious adverse events, including nine deaths, in patients receiving 1,000 and 2,000 mg twice-daily ELND005. Transition was down C$3.76 (45%) to C$4.63 on the day. On NASDAQ, the stock lost $3.50 (44%) to $4.41. ...